Therapy: Hydroxychloroquine in SLE: Old drug, new perspectives

Nature Reviews Rheumatology

Volumn 6, Issue 1, 2010, Pages 10-11

  Dörner, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CELL SURFACE RECEPTOR; CHLOROQUINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; HYDROLASE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANTIBACTERIAL ACTIVITY; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; CELL PH; CELLULAR IMMUNITY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; IMMUNOMODULATION; INFECTION; INNATE IMMUNITY; LUNG TOXICITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RETINA DISEASE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIMALARIALS; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 75149143628     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.235     Document Type: Short Survey

References (10)

1. James, J. A. et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16, 401-409 (2007).
2. Kaiser, R., Cleveland, C. & Criswell, L. A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68, 238-241 (2009).
3. Ruiz-irastorza, G. et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577-583 (2006).
4. Siso, A. et al. Previous antimalarial therapy in patients diagnosed with lupus nephiritis: influence on outcomes and survival. Lupus 17, 281-288 (2008).
5. Tsakonas, e. et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine study Group. Lupus 7, 80-85 (1998).
6. Pons-estel, G. J. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXv, data from a multiethnic Us cohort. Arthritis Rheum. 61, 830-839 (2009).
7. Ruiz-irastorza, G., Egurbide, M. V., Olivares, N., Martinez-Berriotxoa, A. & Aguirre, C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 47, 920-923 (2008).
8. Bultink, I. E. M. et al. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res. Ther. 8, R183 (2006).
9. Smitten, A. L. et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J. Rheumatol. 35, 387-393 (2008).
10. Rolain, J. M., Colson, P. & Raoult, D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int. J. Antimicrob. Agents 30, 297-308 (2007).